BioWorld

Sep. 21, 2006

Awaiting Genasense Decision, Genta Gets $16M In Stock Sale

The pinchpenny public market is pushing more firms to take the route of Solexa Inc., which gained a pledge for $75 million in a stock equity financing from busy Azimuth Opportunity Ltd. (BioWorld Today) Read More

Solexa Gains $75M Equity Line In Deal With Azimuth

Protease Snipping Amyloid Plaques, But Not Precursor

HELP Votes Unanimously On FDA's von Eschenbach

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...